Drugs / CD19 t-haNK
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05618925 | Aug 2025 → May 2026 overdue | non-Hodgkin lymphoma | ImmunityBio, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07556757 | Apr 2025 → Dec 2028 expected | leukemia | ImmunityBio, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06334991 | Aug 2024 → Oct 2027 expected | non-Hodgkin lymphoma | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04052061 | Sep 2019 → Sep 2021 | diffuse large B-cell lymphoma, large B-cell lymphoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07477366 | Apr 2026 → Dec 2027 expected | indolent B-cell non-Hodgkin lymphoma | ImmunityBio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07125872 | Nov 2025 → May 2027 expected | B-cell non-Hodgkin lymphoma | ImmunityBio, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 t-haNK | “CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19” NCT05618925 ↗ |
| Action | Deplete | “enhanced CD16-targeted ADCC capabilities” NCT05618925 ↗ |
| Modality | Cell therapy | “human, allogeneic, NK cell line” NCT05618925 ↗ |
| Route | Intravenous | “CD19 t-haNK- IV Administration” NCT07125872 ↗ |
| Target | CD19 | “engineered to express a CAR targeting CD19” NCT05618925 ↗ |